Peptinovo
Ann Arbor, US · 2 known investors
Peptinovo develops a patented drug delivery platform (PALM carrier technology) intended to improve the efficacy of approved chemotherapies for a range of solid tumors while reducing serious side effects. Its lead candidate, PNB-281, pairs its carrier with paclitaxel, with additional chemotherapy drug candidates in development.
Founders & leadership
RH
REYNOLD HOMANExecutive
BE
BILL ELLIOTTExecutive
ST
STEVE TOKAZExecutive
Board
DR
DAVID ROMENESCOBoard director
FB
FRED BROWNBoard director
Investors · 2
Reported raises · per SEC filings
Form D private placements$2.3M disclosed across 2 rounds · 2021–2024
▶$1.3MraisedDec 2024 · 12 investors · BiotechnologyRule 506(c)
▶$1.3MraisedDec 2024 · 12 investors · Biotechnology
Rule 506(c)Officers, directors & promoters on the filing
- DAVID ROMENESCODirector
- FRED BROWNDirector
- REYNOLD HOMANExecutive Officer, Director
- BILL ELLIOTTExecutive Officer
- STEVE TOKAZExecutive Officer, Director
- Offering amount
- $10M
- Amount sold
- $1.3M
- First sale
- Sep 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06c
▶$955KraisedJun 2021 · 12 investors · BiotechnologyRule 506(b)
▶$955KraisedJun 2021 · 12 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- STEVE TOKAZDirector
- REYNOLD HOMANExecutive Officer, Director
- Amount sold
- $955K
- First sale
- Jun 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 5
by search overlapClinovo7 shared keywordsClinovo provides clinical trial workforce solutions for biotech sponsors and CROs, offering staff augmentation, functional service provider (FSP) models, and AI-powered digital teammates (ClinAI). Its services support clinical operations across trial stages, from early-stage rare disease studies to late-stage oncology and multi-site programs.
Bioworld4 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Synnovation Therapeutics4 shared keywordsA drug discovery company founded by an experienced medicinal chemistry team with expertise in successful pharmaceutical development and clinical advancement.
Northwest Biotherapeutics3 shared keywordsNorthwest Biotherapeutics is a clinical-stage biotechnology company developing personalized cancer vaccines, marketed under the DCVax platform, that use activated dendritic cells to treat a range of solid tumor cancers. Its product lines include DCVax-L, DCVax-Direct, and DCVax-Prostate.
Vitanova Biomedical3 shared keywordsVitanova Biomedical develops cancer treatments based on a proprietary light-activated intracellular acidosis (LAIA) therapy that uses upconverting nanoparticles and deep-penetrating light to induce cancer cell death. The company operates in the biomedical and oncology therapeutics space.
Companies competing with Peptinovo for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Peptinovo do?
- Peptinovo develops a patented drug delivery platform (PALM carrier technology) intended to improve the efficacy of approved chemotherapies for a range of solid tumors while reducing serious side effects. Its lead candidate, PNB-281, pairs its carrier with paclitaxel, with additional chemotherapy drug candidates in development.
- Who are Peptinovo's investors?
- Peptinovo's investors include ID Ventures, WMU Biosciences Research & Commercialization Center.
- How much funding has Peptinovo raised?
- Peptinovo has disclosed $2.3M raised across 2 rounds.
- Where is Peptinovo headquartered?
- Peptinovo is headquartered in Ann Arbor, US.